AbbVie reports SAPPHIRE-I HCV results

|About: AbbVie Inc. (ABBV)|By:, SA News Editor

AbbVie (ABBV) is out with data from SAPPHIRE-I (that's the first of six 3D Phase 3 GT1 HCV trials).

SVR12 rates: 95% in GT1a and 98% in GT1b.

Regulatory submissions expected in Q2 of next year. (PR)

Worth watching on the news: Enanta (ENTA), which discovered one of the regimen's components (ABT-450) as part of an ongoing collaboration with ABBV.